🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The association between statin use, genetic variation, and prostate cancer risk nature.com/articles/s4139… This study investigated the relationship between statin use and #ProstateCancer risk, with a focus on potential genetic 🧬modifiers of this association. Using clinical and

Come join us!!!

The Department of Urology at Cedars-Sinai faculty & trainees have a packed schedule of posters & presentations in Vegas 🎲🎰 ✈️Safe travels everyone! Amer. Urol. Assn. #AUA25

Fantastic post hoc analysis of #EMBARK trial by Dr. Stephen Freedland, MD T returns to ≥175 ng/dL after 36 weeks of treatment suspension, in both Enza combo and Leuprolide alone arms. IMR Cedars-Sinai Judd Moul #AUA2025 #prostatecancer

New study at #AUA2025 showing GLP1 agonists linked with lower metastatic spread and better survival in patients with type 2 diabetes and #prostatecancer. Intriguing……makes sense but lots of confounding in these kind of data. Time for RCTs.

Amazing!!!!!!! Cancer at Cedars-Sinai

🔬The Cancer at Cedars-Sinai GU oncology Disease Research Group had a retreat to... 💡Generate new ideas 🤝Plan collaborations 💁‍♂️Share experiences ⭐️Lots of great things to come! Prostate Cancer Foundation UroToday.com Department of Surgery at Cedars-Sinai Cedars-Sinai Academic Medicine Cedars-Sinai

Despite his age & ominous-sounding disease, Biden has reason for optimism about his aggressive #prostatecancer diagnosis, according to experts. The apparent absence of other symptoms is a potentially favorable finding. Alicia Morgans, MD, MPH Stephen Freedland, MD medpagetoday.com/hematologyonco…

Always great to sit down with Declan Murphy to discuss the latest findings from the #EMBARK study which established enzalutamide as the new standard of care for patients with high risk BCR and cinHSPC (conventional imaging negative hormone sensitive #prostatecancer).

No clear benefit to adding docetaxel to long term ADT for high-risk or very high-risk #prostatecancer patients getting #radiation. Can use #abiraterone for the highest risk groups, but still an unmet need of how to improve outcomes for these patients. #ASCO2025

New B7H3 targeted therapy shows early suggestion of efficacy and reasonable safety in #mCRPC patients. More research needed but we certainly need new mechanisms of action! #ASCO25

Targeting KLK2, an antigen specific to the #prostate in #mCRPC with a bispecific antibody showed early suggestion of efficacy with importantly very limited cytokine release syndrome (CRS). The lack of significant CRS is very notable. Excited to see where this will go. #ASCO25

Excited to present new data from #EMBARK showing that in high risk BCR #prostatecancer patients that #enzalutamide alone has clinical benefits regardless of how you got to high risk BCR. #ASCO25

Important real world data that even if PSA drops 90% in mHSPC - that is not good enough unless PSA is <0.2. Let’s set the bar correctly! <0.2 is the goal - anything less is not good enough. ADT + ARPI much more likely to get PSA <0.2. #ASCO25

Phase 3 of novel viral vector in #prostatecancer pts getting XRT. Intermediate to high-risk. Despite slide title - only helps w/o ADT but not w/ADT. Curves separate at 24 mos when biopsies done. Unlikely to help high risk w/ADT but may replace ADT for intermediate risk? #ASCO25

Nice analysis from IRONMAN matching our VA results presented yesterday: in mHSPC - if the PSA is not <0.2 that is bad. Let’s set the bar correctly- the goal is PSA <0.2. PSA <0.1 does even better! #ASCO25

Updated results from #ARCHES in mHSPC showing sustained benefits of #enzalutamide with minimum 5 year followup. 3 year survival benefit in high volume disease! Amazing results! Andrew Armstrong Arun Azad #ASCO25

Primary results from phase 3 #AMPLITUDE trial showing significant benefits to adding #niraparib, a #PARPi, to mHSPC patients with HRR mutations. Great to have new options to treat #prostatecancer pts who have HRR mutations which portends a poor prognosis. #ASCO25

Incredible work, Cosimo De Nunzio and team!!! Highest impact factor ever for Prostate Cancer and Prostatic Diseases !!!

👏Congrats to our graduating chiefs! Peris Castañeda, MD ➡️Recon fellowship Lahey Urology Jeremiah Dallmer MD ➡️Andrology fellowship Indiana University Department of Urology 👨‍🏫& congrats Michael Ahdoot MD for the faculty teaching award